Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 21, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 12, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Aug 12, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record98815 flagged findings
Reported transactions (Form 4)80since Feb 1, 2023 · and 9 other holdings
Corporate events (8-K)30since Jun 18, 2019
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-07-16capital return (buybacks/dividends)recentOpen filing ↗“…common shares, which repurchases may come in the form of a tender offer (including a modified “Dutch Auction” tender offer),…”
+1 more passage from the same document
- “…negotiated transactions, accelerated share repurchases or other means. The specific form(s) of any such transaction(s) remains…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 988)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 7, 26SCHEDULE 13G/A ↗Passive stake · Morgan Stanley · 12.2% · event on Sep 30, 26 · amendment
- Oct 5, 26SCHEDULE 13D/A ↗Stake with intent to influence · Roivant Sciences Ltd. · 19.5% · event on Oct 1, 26 · amendment
- Oct 5, 26Form 4 ↗Insider transaction
- Oct 1, 26SC TO-I/A ↗Merger, acquisition or tender offer · amendment
- Sep 30, 26SC TO-I/A ↗Merger, acquisition or tender offer · amendment
- Sep 4, 26SCHEDULE 13G ↗Passive stake · Whitefort Capital Master Fund, LP · 8.0%
- Aug 24, 26SC TO-I ↗Merger, acquisition or tender offer
- Aug 21, 268-K ↗Current report · Other events
- Aug 12, 2610-Q ↗Quarterly report
- Aug 12, 268-K ↗Current report · Results
- Aug 12, 26SCHEDULE 13G/A ↗Passive stake · Morgan Stanley · 8.8% · event on Jun 30, 26 · amendment
- Jul 16, 268-K ↗Current report · A material agreement was terminated
- May 27, 268-K ↗Current report · A senior executive left or was appointed
- May 15, 26SCHEDULE 13G/A ↗Passive stake · Two Seas Capital LP · 9.4% · event on Mar 31, 26 · amendment
- May 13, 2610-Q ↗Quarterly report
988 filings on record, the oldest from Nov 12, 10.
Listing the 25 most recent filings of the 988 on record.
22836
- Jul 16, 26A material agreement was terminated+3 more in the same filing8-K 1.02 ↗
- May 27, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 3, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Aug 6, 25A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Jun 25, 25A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Apr 3, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 3, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
10 senior executive changes2022 – 2025show all 10hide
- Feb 25, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Oct 11, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 28, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 2, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 4, 24A senior executive left or was appointed8-K 5.02 ↗
- Nov 7, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jul 12, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 27, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Oct 24, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 31, 22A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 13, 21Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Dec 10, 21Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Nov 12, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 1, 21A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
8 older filings not shown · The record reaches back to Aug 26, 14.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Feb 8, 18Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Sep 28, 16Listing notice (8-K 3.01)8-K 3.01 ↗
The full record holds 2 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Roivant Sciences Ltd.19.5%Oct 1, 26SCHEDULE 13D/A ↗2 earlier filings
- Whitefort Capital Master Fund, LP8.0%Apr 24, 26SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Morgan Stanley12.2%Sep 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
- Two Seas Capital LP9.4%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- Whitefort Capital Master Fund, LP8.0%Sep 4, 26SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
- Feb 4, 25Sell$37KJ. Christopher NaftzgerGeneral Counsel and CCO↗
- Feb 4, 25Sell$78KMichael J. McElhaughInterim President & CEO↗
- Feb 4, 25Sell$64KKaren SimsChief Medical Officer↗
- Feb 4, 25Sell$73KDAVID C HASTINGSChief Financial Officer↗
- Aug 14, 24Sell$33KKEITH S MANCHESTER↗
- Feb 2, 24Sell$24KMichael J. McElhaughInterim President & CEO↗
- Feb 2, 24Sell$23KMichael J. SofiaChief Scientific Officer↗
- Feb 2, 24Sell$22KDAVID C HASTINGSChief Financial Officer↗
- Feb 2, 24Sell$10KKaren SimsChief Medical Officer↗
Stock compensation, tax and giftsshow the 31 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 1, 26Other$44.8MRoivant Sciences Ltd.↗
- Oct 1, 26Other$123KLindsay AndroskiPresident and CEO↗
- Oct 1, 26Other$86KRoger Sawhney↗
- Oct 1, 26Other$240KTuan NguyenChief Financial Officer↗
- Oct 1, 26Other$90KRobert A Beardsley↗
- Sep 18, 26Compensation$168KRobert A Beardsley↗
- Sep 18, 26Compensation$334KRobert A Beardsley↗
- Sep 18, 26Tax$502KRobert A Beardsley↗
- Sep 18, 26Compensation$175KRoger Sawhney↗
- Sep 18, 26Compensation$334KRoger Sawhney↗
- Sep 18, 26Tax$510KRoger Sawhney↗
- Sep 18, 26Compensation$927KTuan NguyenChief Financial Officer↗
- Sep 18, 26Compensation$121KTuan NguyenChief Financial Officer↗
- Sep 18, 26Tax$1.0MTuan NguyenChief Financial Officer↗
- Sep 18, 26Compensation$373KLindsay AndroskiPresident and CEO↗
- Sep 18, 26Compensation$46KLindsay AndroskiPresident and CEO↗
- Sep 18, 26Tax$418KLindsay AndroskiPresident and CEO↗
- Feb 2, 26Compensationamount n/aLindsay AndroskiPresident and CEO↗
- Feb 2, 26Compensationamount n/aTuan NguyenChief Financial Officer↗
- Feb 14, 25Compensationamount n/aKaren SimsChief Medical Officer↗
- Feb 14, 25Compensationamount n/aDAVID C HASTINGSChief Financial Officer↗
- Feb 14, 25Compensationamount n/aMichael J. McElhaughInterim President & CEO↗
- Feb 14, 25Compensationamount n/aJ. Christopher NaftzgerGeneral Counsel and CCO↗
- Aug 14, 24Compensation$31KKEITH S MANCHESTER↗
- Feb 1, 24Compensationamount n/aMichael J. McElhaughInterim President & CEO↗
- Feb 1, 24Compensationamount n/aMichael J. SofiaChief Scientific Officer↗
- Feb 1, 24Compensationamount n/aDAVID C HASTINGSChief Financial Officer↗
- Feb 1, 24Compensationamount n/aKaren SimsChief Medical Officer↗
- Feb 1, 24Compensationamount n/aJ. Christopher NaftzgerGeneral Counsel and CCO↗
- Feb 1, 23Compensationamount n/aElizabeth HowardEVP, GC, Compliance↗
- Feb 1, 23Compensationamount n/aWilliam H. CollierPresident and CEO↗
The full record holds 43 transactions and goes back to Feb 1, 23.
Its sector and its market
Arbutus Biopharma Corporation among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Arbutus Biopharma Corporation, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Arbutus Biopharma Corporation in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 988 documents on file, from Nov 12, 2010 to Oct 7, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.